Navigation Links
SPRI Clinical Trials Now Enrolling Patients for Study of New Treatment for Depression
Date:10/15/2007

Patient Recruitment Starting Now -- For More Information, Call 888-345-7774

or Visit Our Website at http://www.spristudy.com

NEW YORK, Oct. 15 /PRNewswire/ -- SPRI Clinical Trials announced today that it is now screening patients for enrollment in the parAGOn Clinical Trial Program, which will start with two Phase III studies to evaluate the efficacy, safety and tolerability of agomelatine, a novel, investigational, once-daily medication for the treatment of Major Depressive Disorder (MDD). The 8-week, randomized, placebo-controlled studies are sponsored by Novartis Pharmaceuticals Corporation, and each of the two Phase III studies will include 490 patients from approximately 50 centers.

This investigational new drug targets both melatonin receptors and serotonin (5-HT2c) receptors.

The parAGOn Clinical Trial Program is open to patients between the ages of 18 and 70 who are experiencing MDD and meet other eligibility criteria. Eligible patients will be equally randomized to receive either treatment with agomelatine 25 mg, agomelatine 50 mg or placebo once daily for 8 weeks. Patients who complete the eight-week double-blind treatment phase may also participate in a 52-week open-label extension of the study.

MDD is the most common mood disorder, affecting approximately 15 million American adults, according to the National Alliance on Mental Illness. Common symptoms include: depressed mood, loss of interest in daily activities, poor concentration, weight loss (or gain), decrease of appetite, sleep disturbance, feelings of worthlessness and /or of guilt, and suicidal ideation. Episodes of depression may be chronic and recurrent, according to the National Institute of Mental Health.

Contact Dr. Nick Vatakis at 888-345-7774 for more information about the ParAGOn Clinical Trial Program.


'/>"/>
SOURCE SPRI Clinical Trials
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017  Akcea Therapeutics, a subsidiary ... initiation of a Phase 2b dose-ranging study of AKCEA-APO(a)-L ... disease. The goal of the study is to determine ... Rx in a planned Phase 3 cardiovascular outcome ... of Akcea,s strategic collaboration with Novartis to develop and ...
(Date:3/30/2017)... DUBLIN , Mar 30, 2017 ... "Hemodialysis And Peritoneal Dialysis Market Size & Forecast, By Type ... (Home-based, Hospital-based), And Trend Analysis From 2014 To 2025" ... ... market is expected to reach USD 108.5 billion by 2025. ...
(Date:3/29/2017)... Research and Markets has announced the ... Forecast By Type (Insource IONM, Outsource IONM), By Region And ... offering. ... The global Intraoperative Neuromonitoring (IONM) market is expected to ... is anticipated to witness significant growth in the forecast period, ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 2017 , ... According to the American Society of Plastic Surgeons (ASPS), over ... top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, it’s ... the next 8-10 weeks. For anyone considering a hair removal procedure, there are a ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, ... conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue ... ET. This conference discusses strategies to prevent readmissions in light of the most ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans ... been used for thousands of years. , "The West has caught on, and has ... How to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
(Date:3/29/2017)... Indianapolis, IN (PRWEB) , ... March 29, 2017 ... ... Benefits Study, this webinar provides insight into the challenges employers face in trying ... the complexity of managing employee benefits programs? Adding to the growing complexity, ...
Breaking Medicine News(10 mins):